Assertio Holdings, Inc. Material Event - What Happened

If you follow Assertio Holdings (ASRT), you may have seen the big news: the company has agreed to be bought out. I’ve broken down the details so you don’t have to dig through the legal paperwork.

1. What happened?

Assertio Holdings agreed to be acquired by Garda Therapeutics, Inc. On May 1, 2026, the companies simplified the deal. Assertio shareholders will now receive $21.80 per share in cash. This update removes the "contingent value rights," which would have tied your payout to future company performance. By removing those variables, the deal is now a simple, all-cash acquisition.

2. When did it happen?

The companies announced the updated agreement on May 1, 2026. The formal "tender offer"—the process where you submit your shares to be bought—will begin after the company files the necessary paperwork with the SEC.

3. Why did it happen?

Assertio’s Board of Directors unanimously approved the deal. They believe the $21.80 cash price offers shareholders immediate, certain value. This structure removes the risks tied to Assertio’s long-term product pipeline. To ensure the deal goes through, major shareholders and board members have signed agreements promising to sell their shares.

4. What about the company's debt?

Assertio has $40 million in convertible notes due in 2027. As part of the merger, Assertio is offering to buy these notes back from investors at 100% of their face value, plus any unpaid interest. This debt repayment is required to clean up the company’s finances before it becomes a private subsidiary of Garda Therapeutics.

5. Why does this matter?

This is a "take-private" deal. Assertio will no longer be a public company. Once the deal closes, the stock will be removed from the Nasdaq. For investors, this puts a "ceiling" on the stock price near $21.80, as the market price will hover near the buyout price until the deal closes.

6. Who is affected?

• Investors: If you own shares, you will receive $21.80 in cash when the deal closes. The target date is July 2, 2026, pending regulatory approval.
• Employees: Stock options and restricted stock units (RSUs) will be cashed out. Options with a strike price below $21.80 will be settled for the difference, and RSUs will be paid out at $21.80 each.
• The Market: Garda Therapeutics has secured financing for the deal, which makes a successful closing more likely.

7. What should you do next?

• Watch for the "Tender Offer": Your brokerage will send you "Offer to Purchase" documents. These explain how to submit your shares.
• The Price Gap: The stock might trade slightly below $21.80. This small gap reflects the time remaining until the July 2, 2026, closing date and any remaining regulatory steps.
• Stay Informed: Check the Assertio website for the official Schedule 14D-9. This document contains the Board’s formal recommendation and final details.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and is not professional investment advice. Always do your own research before making any trades!